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Background: Mononuclear platinum anticancer agents hold a pivotal place in the treatment of many forms of
cancers, however, there is a potential to improve response to evade resistance development and toxic side effects.
BBR3464 is a promising trinuclear platinum anticancer agent, which is a polyamine mimic. The aim was to
investigate the influence of polyamine pool reduction on the cytotoxic effects of the trinuclear platinum complex
BBR3464 and cisplatin. Polyamine pool reduction was achieved by treating cells with either the polyamine
biosynthesis inhibitor α-difluoromethylornithine (DFMO) or the polyamine analogue N1,N11-diethylnorspermine
(DENSPM).
Methods: A human squamous cell carcinoma cell line, LU-HNSCC-4, established from a primary head and neck
tumour was used to evaluate cellular effects of each drug alone or combinations thereof. High-performance liquid-
chromatography was used to quantify intracellular polyamine contents. Inductively coupled mass spectroscopy was
used to quantify intracellular platinum uptake. Cells were exposed to DFMO or DENSPM during 48 h at
concentrations ranging from 0 to 5 mM or 0 to 10 μM, respectively. Thereafter, non-treated and treated cells were
exposed to cisplatin or BBR3464 during 1 h at concentrations ranging from 0 to 100 μM. A 96-well assay was used
to determine cytotoxicity after five days after treatment.
Results: The cytotoxic effect of BBR3464 on LU-HNSCC-4 cells was increased after cells were pre-treated with
DENSPM or DFMO, and the interaction was found to be synergistic. In contrast, the interaction between cisplatin
and DFMO or DENSPM was near-additive to antagonistic. The intracellular levels of the polyamines putrescine and
spermidine were decreased after treatment with DFMO, and treatment with DENSPM resulted in an increase in
putrescine level and concomitant decrease in spermidine and spermine levels. The uptake of BBR3464 was
significantly increased after pre-treatment of the cells with DFMO, and varied dependent on the concentration of
DENSPM. The uptake of cisplatin was unchanged.
Conclusions: Taken together, these results demonstrate that combinations of polyamine synthesis inhibitors with
BBR3464 appear to be a promising approach to enhance the anticancer activity against HSCC.
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Although mononuclear platinum anticancer agents hold
a pivotal place in the treatment of many forms of can-
cers, there is a potential to improve response and sur-
vival in patients. Development of resistance to therapy
and toxic side effects are major problems, which have
prompted research into new platinum drugs, displaying
different mechanisms of action. One such compound is
BBR3464, which is a promising trinuclear platinum
anticancer agent. It is built up by three square-planar
platinum units and it forms different types of adduct
with DNA [1]. The structure of BBR3464 classifies it as
a polyamine analogue. Based on the result from a
screening panel with 60 cell lines, the mechanism of
action of BBR3464 has been suggested to differ com-
pared to cisplatin [2]. Furthermore, BBR3464 has been
shown to be more potent than cisplatin [2,3] and to
circumvent the resistance to cisplatin in a number of
tumour cell lines and xenografts [4-7]. BBR3464 has
also showed superior activity against p53-mutant
tumours [8].
A fruitful way of increasing the response rate of
tumours is to use complementary combinations of
drugs, e.g. an antimetabolite and one or more antican-
cer agents. The platinum anticancer drugs cisplatin and
oxaliplatin have been successfully combined with e.g. 5-
fluorouracil (5-FU) in head and neck and colon cancer,
respectively [9]. The combination of cisplatin or carbo-
platin with paclitaxel is the most common first-line
treatment for patients with advanced ovarian cancer.
For non-small-cell lung cancer combination chemother-
apy involving platinum agents is considered to be im-
portant, however, limited by toxicity and resistance
[10]. BBR3464 was successfully combined with 5-FU
against a human gastric tumour model in preclinical
in vivo studies. However, a phase I open-label dose-es-
calating study could not support administration of
BBR3464 in combination with protracted venous infu-
sion of 5-FU [11].
Naturally occurring polyamines have been recognized
as important constituents for the proliferation of normal
and malignant cells. Thus, the polyamine metabolic path-
way has been an attractive target for the treatment of
cancer. This has resulted in the development of a wide
range of inhibitors of polyamine biosynthesis, the most
thoroughly investigated being α-difluoromethylornithine
(DFMO) [12]. Treating cells with DFMO, which irrevers-
ibly binds to the polyamine biosynthetic enzyme orni-
thine decarboxylase (ODC), reduces the polyamine levels
resulting in inhibition of cell proliferation in vitro
[12,13]. Another group of substances interfering with
polyamine metabolism are polyamine analogues. N1,N11-
Diethylnorspermine (DENSPM) is a spermine analogue,
which is taken up by the cellular polyamine transportsystem and thus is accumulated in the cell [14-16]. Intra-
cellular DENSPM accumulation results in activation of
the polyamine catabolic enzyme spermine/spermidine
N1-acetyltransferase (SSAT) resulting in the catabolism
of the natural polyamines putrescine, spermidine and
spermine [14-16]. DENSPM can however not take over
the function of the natural polyamines. In addition to
stimulating catabolism, DENSPM also exerts a feedback
inhibition of polyamine biosynthesis. DENSPM treat-
ment as DFMO treatment results in inhibition of cell
proliferation and has been demonstrated to induce apop-
tosis [17,18].
Cellular polyamine homeostasis is a very complex
process involving biosynthesis, catabolism and trans-
port through the cell membrane [19]. Thus, when cells
are depleted of their natural polyamines, the polyamine
transport system is up-regulated as a means for the
cell to normalize its polyamine pools [19-21]. Since
polyamines are continuously supplied from the gastro-
intestinal tract through food and bacteria, this is a
major obstacle for effective inhibition of tumour-cell
growth in vivo by use of biosynthesis inhibitors as sin-
gle chemotherapeutic agents. However, an up-regulated
polyamine transport system may be exploited in the
search for new chemotherapeutic drugs. Cisplatin has
been combined with inhibitors of the polyamine bio-
synthetic pathway with contradictory anti-tumour effi-
cacies [22-28].
BBR3464 is a new polyamine cisplatin analogue [1].
Because of this, we hypothesise that BBR3464 is, at least
to some extent, transported into the intracellular com-
partment by the same transport system as the naturally
occurring polyamines. Based on that hypothesis, we
investigated the antitumour effect of BBR3464 in com-
bination with DFMO or DENSPM against a squamous
carcinoma cell line of the head and neck (HNSCC), and
compared that with cisplatin.Results
Effect of DFMO and DENSPM on polyamine levels
Treatment with 0.1 μM DENSPM or 50 μM DFMO
affected the polyamine pools as have been previously
observed [12]. DFMO treatment reduced the putrescine
content to an undetectable level already after 24 h of
treatment (Figure 1). The spermidine pool was almost
depleted by DFMO treatment after 48 hours of treat-
ment while the spermine pool was essentially unaffected.
Treatment with DENSPM resulted in increased level of
putrescine, and unchanged levels of spermidine and
spermine (Figure 1). DFMO treatment reduced the total
pool of polyamines. Based on these date we choose a 48
hours pre-treatment period with DENSPM or DFMO
before treatment with cisplatin or BBR3464.
Figure 1 The effect of 50 μM DFMO or 0.1 μM DENSPM
treatment on the polyamine content of LU-HNSCC-4 cells. The
cells were seeded and incubated for 24 h before addition of DFMO
or DENSPM at time 0 in the figure. The symbols are the means from
one experiment with n = 3 and bars represent ± SD. Control cells
(□); DFMO-treated cells (■); DENSPM-treated cells (●).
Table 1 Effect of DFMO or DENSPM on intracellular
accumulation of cisplatin and BBR 3464 in LU-HNSCC-4
cells.a
Pre-treatment Platinum accumulation (μg Pt/106 cells)
Cisplatin BBR 3464
Control medium 0.8 ± 0.1 1.0 ± 0.1
5 μM DENSPM 0.8 ± 0.1 1.2 ± 0.1
10 μM DENSPM 0.9 ± 0.1 0.7 ± 0.2
25 μM DFMO 0.9 ± 0.1 2.2 ± 0.3*
75 μM DFMO 0.8 ± 0.1 2.4 ± 0.4*
aCells were grown in the absence of DENSPM or DFMO 48 h and then the
medium was changed and fresh medium added before a 1 h exposure to
cisplatin (7.5 μM) or BBR 3464 (0.5 μM). Values are mean from three
independent experiments in each of which there were at least two
independent samples ± SEM. * p< 0.002.
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cisplatin and BBR3464
The effect of DFMO or DENSPM treatment for 48 h on
intracellular accumulation of cisplatin or BBR3464 after
a 1 h exposure time was investigated. A significant in-
crease in platinum content was found in cells that had
been growing in the presence of 25 or 75 μM DFMO for
48 h before addition of BBR3464 (p< 0.002) as com-
pared with cells grown in control medium (Table 1). The
cellular level of BBR3464 was found to be slightly higher
in cells that had been growing in the presence of 5 μM
DENSPM for 48 h, while 10 μM DENSPM decreased the
platinum accumulation as compared with control cells.
When cisplatin accumulation was investigated, neither
DFMO nor DENSPM were found to influence the
amount of platinum in the cells (Table 1).Cytotoxicity studies
The cytotoxic effect of a 1 h exposure to BBR3464 or
cisplatin, or a 48 h exposure to DFMO or DENSPM, was
investigated. BBR3464 was found to be one order of
magnitude more cytotoxic than cisplatin (IC50: 1.2 vs.
17 μM, Figure 2). The dose-response curves for DFMO
and DENSPM treatment alone for 48 h on the cell
growth of LU-HNSCC-4 are shown in Figure 3. The
IC50 concentrations of the two drugs were 80 μM
DFMO and 0.32 μM DENSPM.
In the combination experiments, we used concentra-
tions of DFMO (10, 25, and 50 μM) or DENSPM (0.075,
0.10, and 0.20 μM) that had a< 40% effect on cell
growth on their own. When these concentrations of
DFMO or DENSPM were combined with BBR3464, cell
viability decreased compared with BBR3464 treatment
alone, as illustrated in Figure 4. We found that the IC50
concentrations obtained from the drug combinations to
be within or to the left of the envelope of additivity in
the isobolograms, Figure 4, indicating additive to syner-
gistic effects.
When 0.075, 0.10, or 0.20 μM DENSPM was com-
bined with cisplatin we found the cytostatic effect of cis-
platin to increase, as illustrated in the dose-response
curves in Figure 5. From these curves, the obtained IC50
concentrations were found to be near the envelope of
additivity, indicating near-additive effects. When 10, 25,
and 50 μM DFMO were combined with cisplatin, cell
viability decreased for 10 and 25 μM DFMO and
increased for 50 μM DFMO compared with cisplatin
alone, as illustrated in the dose-response curves in
Figure 5. The obtained IC50 values were found to be on
the right of the envelope of additivity, indicating antag-
onistic to protective effects, Figure 5.Discussion
The results presented here indicate that combination of
polyamine synthesis inhibitors with BBR3464, investigated
Figure 2 Growth inhibition of LU-HNSCC-4 cells exposed to varying concentration of cisplatin (▲) or BBR3464 (♦). Cells that had been
grown in 96-well plates for 72 h were treated with the drugs at the indicated concentrations for 1 h. Thereafter the drug containing medium was
removed and the cells incubated for 72 h before cell growth was evaluated with an MTT assay. Values represent averages of triplicate
experiments, and error bars indicate SEM.
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head and neck tumour, may be a potential regimen for head
and neck cancer chemotherapy. A clear synergistic effect
was observed when DFMO or DENSPM were combined
with BBR3464. In contrast, for combinations with cisplatin
the effect was only additive or antagonistic (protective in
one case). Interestingly, since DENSPM and BBR3464 are
polyamine analogues a competition in uptake and thus an-
tagonistic effects could have been expected. However, it
should be noted that the combination was sequential i.e.
the cells were not treated simultaneously with the two com-
pounds in any of the experiments. Thus, there should not
be any competition in uptake between DENSPM and
BBR3464.Figure 3 Growth inhibition of LU-HNSCC-4 cells exposed to varying c
well plates and 24 hours later DFMO or DENSPM were added at the indica
Thereafter the drug containing medium was removed and the cells incuba
Values represent averages of four or more experiments, and error bars indiOur study confirms previous results of higher antitumour
effect of BBR3464 compared with cisplatin against in vitro-
cultured tumour cell lines [2,4-8,29-31]. Several mechan-
isms for the higher antitumour effect of BBR3464 have
been suggested, e.g. increased platinum binding to DNA,
different types of DNA adducts, and that mechanisms
involved in the repair of these adducts are different from
those of cisplatin
Increased polyamine levels are associated with increased
proliferation rate, decreased apoptosis and increased ex-
pression of genes affecting tumour invasion and metastasis
[32]. Thus, the concept of treating cells with compounds
that decrease the polyamine pools has been one approach
to achieve inhibition of tumour growth. In vitro, theoncentration of DFMO (●) or DENSPM (■). Cells were seeded in 96-
ted concentrations. The cells were incubated with the drugs for 48 h.
ted for 72 h before cell growth was evaluated with an MTT assay.
cate SEM.
Figure 4 Growth inhibition of LU-HNSCC-4 cells following treatment with BBR3464 alone or in combination with (A) DENSPM and (B)
DFMO. Cells were seeded in 96-well plates and 24 hours later DFMO or DENSPM were added at the indicated concentrations. The cells were
incubated with the drugs for 48 h. Thereafter the cells were treated with BBR3464 at the indicated concentrations. After one 1 h of BBR3464
treatment, the drug containing medium was removed and the cells incubated for 72 h before cell growth was evaluated with an MTT assay. In
the combination experiments cells were treated with different concentrations of DENSPM: 0 (□), 0.075 (●), 0.10 (♦), or 0.20 (■) μM, or DFMO: 0
(□), 10 (●), 25 (♦), or 50 (■) μM. Values represent average of triplicate experiments, and error bars indicate SEM. Isobolograms (C) and (D) for the
combination of BBR3464 with DENSPM and DFMO, respectively.
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proliferating, is mediated through inhibiting ODC, which
results in depletion of putrescine and spermidine [12]. The
decreased levels of putrescine and spermidine, and the
reduced cell number observed here are in accordance with
this mechanism. DENSPM, which is a spermine analogue,
was developed to inhibit the activity of both ODC and S-
adenosylmethionine decarboxylase. Furthermore, an unex-
pected effect of this analogue was the induction of the poly-
amine catabolic enzyme SSAT. The level of inhibition of
cell proliferation by DENSPM is highly dependent on the
level of induction of SSAT, which results in a massive de-
pletion of the cellular polyamine pool [15]. Furthermore, it
has been suggested that DENSPM replaces native polya-
mines at intracellular locations, without fulfilling their bio-
logical functions [33,34].
Here, we show that the intracellular levels of spermidine
and spermine were reduced, while putrescine was increased
compared to control after cells were exposed to DENSPM.
These changes of the polyamine pools could be explained
by the activated polyamine catabolism, resulting in
decreased levels of spermidine and spermine coupled to
increased levels of putrescine [35]. In our experimentalsetup, DENSPM was found to inhibit cell growth more
compared with DFMO. This result is in accordance with
earlier findings showing greater antiproliferative activity of
DENSPM compared with DFMO [36]. DFMO treatment
reduced the putrescine and spermidine pools while the
spermine pool remained unchanged compared to control.
In fact DFMO treatment slightly reduced the total polya-
mine pool while DENSPM treatment did not. Thus, it
appears that the decreased spermine pool in DENSPM-
treated cells was of importance for growth inhibition pre-
sumably together with the suggestion that DENSPM
replaces native polyamine [33,34].
Although the growth of different tumour cells is sup-
pressed by treatment with polyamine biosynthesis inhibi-
tors and analogues, it has been recognized that tumours
are able to regrow when administration of these com-
pounds is interrupted [12]. Accordingly, polyamine bio-
synthesis inhibitors and analogues may be more useful
as chemotherapeutic agents when combined with an-
other drug. Indeed, sensitization of alkylating agents by
DFMO and DENSPM, have been observed [22-24,37,38].
However, other studies have found only additive or an-
tagonistic effects of combining cisplatin with polyamine
Figure 5 Growth inhibition of LU-HNSCC-4 cells following treatment with cisplatin alone or in combination with DENSPM (A) and
DFMO (B). Cells were seeded in 96-well plates and 24 hours later DFMO or DENSPM were added at the indicated concentrations. The cells were
incubated with the drugs for 48 h. Thereafter the cells were treated with cisplatin at the indicated concentrations. After one 1 h of BBR3464
treatment, the drug containing medium was removed and the cells incubated for 72 h before cell growth was evaluated with an MTT assay. In
the combination experiments cells were treated with different concentrations of DENSPM: 0 (□), 0.075 (●), 0.10 (♦), or 0.20 (■) μM, or DFMO: 0
(□), 10 (●), 25 (♦), or 50 (■) μM. Values represent average of triplicate experiments, and error bars indicate SEM. Isobolograms (C) and (D) for the
combination of cisplatin with DENSPM and DFMO, respectively.
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the discrepancy between these observed results might be
that the interaction of cisplatin and polyamine biosyn-
thesis inhibitors seems to be schedule dependent [24].
However, it has also been proposed that DFMO-induced
polyamine depletions alters the structure of DNA, which
may impair the ability of cisplatinum to crosslink in the
molecule [28].
In this study, we found a clear synergistic effect when
DFMO or DENSPM were combined with BBR3464. In our
experimental setup, cells were pre-treated with DFMO or
DENSPM for 48 h prior to addition of the platinum com-
plex. DFMO produced a larger synergistic effect compared
with DENSPM, as the IC50 values are furthest to the left of
the envelope of additivity in the isobolograms. A possible
explanation for this may be related to the finding of a sig-
nificantly higher platinum uptake in cells that were pre-
treated with DFMO compared with DENSPM-treated and
control cells. This change in cellular accumulation of
BBR3464, as a result of DFMO or DENSPM treatment,
suggests that the transport of BBR3464 in to the cell is
mediated by the polyamine transport system. Interestingly,we found a decreased platinum uptake when cells were
pre-treated with higher concentrations of DENSPM. This
observation may reflect that DENSPM accumulates in the
cell and that those native polyamines, associated with nega-
tively charged molecules, e.g. DNA and RNA are replaced
by the more inert DENSPM molecule. As a consequence,
the ability of BBR3464 to enter into the cell passing through
the polyamine transport system, and subsequently reach
the intracellular targets may be reduced. Also, polyamine
analogue treatment has been shown to induce antizyme,
which would inhibit further uptake of polyamine like mole-
cules since antizyme is an inhibitor of polyamine transport
[12,39]. This may also contribute to the fact that DENSPM
treatment at high concentrations reduces the uptake of
BBR 3463. In contrast, DFMO does not substitute for the
reduced levels of native polyamines. Instead, cells deprived
of polyamines compensate by increasing the uptake of
extracellular polyamines, thus facilitating accumulation of
the cisplatinum polyamine analogue BBR3464 in the cellu-
lar compartment.
In contrast to BBR3464, cisplatin was not found to
interact synergistically with DFMO or DENSPM. At best,
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DENSPM, while antagonistic or protective effects were
found for combinations with DFMO. Here, we found no
difference in accumulation of cisplatin between cells pre-
treated with DFMO or DENSPM and untreated cells.
This finding is reasonable, since it has been demon-
strated that tumour cell uptake of cisplatin is regulated
through the major Cu influx transporter CTR1 [40], and
thus, is not likely to be mediated by the polyamine trans-
port system, as shown in a previous study [41].
Intriguing is the fact that very low concentrations of
DFMO enhanced the uptake and toxicity of BBR3464.
This is very promising from a cancer treatment point of
view where a low dose of DFMO could increase the tox-
icity of BBR3464 substantially. DFMO has been used as
a chemotherapeutic and chemopreventive agent in sev-
eral studies with varying success [42,43]. Ongoing phase
II and III studies show a favourable effect of combining
DFMO and the non steroidal anti-inflammatory drug
sulindac in the chemoprevention of colon cancer devel-
opment in patients with colon adenomatous polyps [44].
Conclusions
Our results argue that polyamine synthesis inhibitors
and polyamine analogues may be useful in cancer
chemotherapy in combination with BBR3464. Since
there is large numbers of polyamine synthesis inhibitors
available there is a rationale for continuous investiga-
tions along this avenue. Also, further experiments with
BBR3464 in combination with polyamine synthesis inhi-
bitors is needed to establish the effect on the growth of
human tumours in vivo.
Methods
Drugs and chemicals
BBR3464 was generously provided by Dr Ernesto Menta
from Novuspharma S.p.A. (Monza, Italy), now Cell Thera-
peutics Europe S.r.I. (Bresso, Italy), and was dissolved in
saline immediately before use. Cisplatin was purchased
from Pharmalink AB (Stockholm, Sweden). DENSPM was
purchased from Tocris Cookson (Bristol, UK), and DFMO
was purchased from Lonza Inc. (Allendale, NJ). DENSPM
and DFMO were dissolved in phosphate-buffered saline
(PBS, GIBCO, Paisly, Scotland) and the pH was adjusted
to 7.4 with NaOH before use.
Cell line and growth conditions
An established tumour line, LU-HNSCC-4, originating
from HNSCC of the floor of the mouth was used in this
study [45]. Cells were maintained in logarithmic growth
as monolayer cultures in DMEM medium (GIBCO) sup-
plemented with 10% heat-inactivated fetal calf serum
and antibiotics (GIBCO) (100 units/ml penicillin and100 units/ml streptomycin), in a humidified 5% CO2 at-
mosphere at 37°C.
MTT assay
The MTT assay based on the tetrazolium dye was used
to evaluate the effect of the drugs on cell growth [46].
Briefly, cells were harvested by trypsinization, electronic-
ally counted (NucleoCounter™, ChemoMetec A/S, Edi-
son, NJ), seeded (1500 cells / well) in 96-well plates, and
allowed to adhere overnight before addition of drug. In
the case of treatment with DENSPM or DFMO alone,
the drugs were added to medium and cells were incu-
bated for 48 h at concentrations ranging from 0 to
10 μM and 0 to 5 mM, respectively. After removal of the
medium containing DFMO or DENSPM, cells were
allowed to regrow in drug-free medium for 72 h before
the cell growth was determined using the MTT assay. In
the case when cells were treated with cisplatin or
BBR3464 alone, drugs were added in medium and cells
were incubated for 1 h at concentrations ranging from 0
to 100 μM or 0 to 10 μM, respectively. Thereafter, the
drug-containing medium was removed, and cells were
allowed to regrow in drug-free medium for 72 h before
cell growth was determined using the MTT assay.
The concentrations of DENSPM and DFMO chosen
for the further studies described below were based on
the results of the MTT assays described above.
In the combination experiments, cells were seeded in
96-well plates and allowed to adhere overnight. Then,
cells were treated with DENSPM (0.075, 0.1, or 0.2 μM)
or DFMO (10, 25, or 50 μM) during 48 h. Thereafter,
the drug containing medium was removed, and cells
were exposed for 1 h to cisplatin or BBR3464, at concen-
trations ranging from 0 to 100 μM or 0 to 10 μM, re-
spectively. After drug removal, cells were allowed to
regrow in drug-free medium for 72 h before the effect
on cell growth was determined and the drug interactions
were analysed by means of isobologram plotting, see
below. The cytotoxicity experiments were performed in
at least triplicate.
Test for synergy
For each experiment, the IC50 values were determined as
the concentration of drug causing a 50% growth inhib-
ition compared to control. For each combination, the
IC50 values were calculated, and the data from these
experiments was analysed using an isobologram method
[47]. In brief, the IC50-isobolgram shows the doses
required to inhibit cell growth by 50% after exposure to
cisplatin or BBR3464 alone, DENSPM or DFMO alone,
or combinations thereof. In this analysis, it was taken
into consideration that the cytostatic effect of each drug
produced non-linear dose-response curves. Therefore,
the area between the two lines in Figures 4 and 5
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each cell survival curve were merged and plotted. Dots
located to the left, within, or to the right of the “enve-
lope of additivity” indicate synergy, additivity and antag-
onism, respectively, between the two drugs.
Intracellular accumulation
For the investigation of the intracellular accumulation of
cisplatin and BBR3464, cells were seeded in tissue cul-
ture dishes (6 cm diameter) in triplicate and 24 hours
later, they were exposed to DENSPM (5 or 10 μM) or
DFMO (25 or 75 μM) or drug-free medium. Forty-eight
hours after DENSPM or DFMO exposure, drug-contain-
ing medium was removed and cells were treated with
0.5 μM BBR3464 or 7.5 μM cisplatin for 1 h. The plat-
inum accumulation was then analysed by inductively
coupled plasma mass-spectrometry (Thermo X7,
Thermo Elemental, Winsford, UK). All accumulation
experiments were performed in at least duplicate and
the experiment was repeated three times. Briefly, cells
were washed three times with ice-cold PBS, harvested by
trypsinization and counted and digested in 70% HNO3
for 2 h at 65°C. The samples were then diluted to a 2%
acid solution before analysis. The samples were intro-
duced in a segment-flow mode and analysed in peak-
jumping mode, 100 sweeps and 1 point per peak, 30 ms
dwell time for platinum (Pt195) and 10 ms dwell time for
bismuth (Bi209) used as an internal standard. The detec-
tion limit calculated as three times the standard devi-
ation (SD) of the blank was 0.02 μg/L. All samples were
prepared in duplicate and the method imprecision, cal-
culated as the coefficient of variation for duplicate mea-
surements, was 1.6%.
Measurement of polyamines
Cells were seeded in tissue culture dishes (6 cm diam-
eter) in triplicate and, 24 hours later, cells were exposed
to DENSPM (0.1 μM) or DFMO (50 μM). Cells were
collected for polyamine analysis at the time of seeding
and then 1 – 3 days after seeding. Briefly, cells were har-
vested, washed three times with ice-cold PBS and
counted. Cell pellets were stored at -20º until analysis.
Chromatographic separation and quantitative determin-
ation of the polyamines in cell extracts in 0.2 M perchlo-
ric acid were carried out using high-performance liquid
chromatography (Hewlett-Packard 1100), with O-phtal-
dialdehyde as the reagent [48]. The experiment was per-
formed twice.
Statistics
All values report the mean ± standard error of the mean
(SEM) unless otherwise specified. Differences between
groups were analysed using ANOVA and then unpairedt-test (RS/1, Brooks Automation, Inc., Chelmsford, MA
U.S.A.).
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